Statin Therapy Decreases Serum Levels of High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-α in HIV-Infected Patients Treated With Ritonavir-Boosted Protease Inhibitors

REFERENCES

• Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92: 2506–2512.
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24: 1228–1230.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS. 2010;24:789–802.
   PubMed Web of Science ®Google Scholar
• Giannarelli C, Klein RS, Badimon JJ. Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis. 2011. doi: 10.1016/j.atherosclerosis.2011.06.003
   Web of Science ®Google Scholar
• Fichtenbaum CJ. Inflammatory markers associated with coronary heart disease in persons with HIV infection. Curr Infect Dis Rep. 2011;13:94–101.
   PubMedGoogle Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
   PubMed Web of Science ®Google Scholar
• Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010;55:615–619.
   PubMed Web of Science ®Google Scholar
• Kablak-Ziembicka A, Przewlocki T, Sokolowski A, Tracz W, Podolec P. Carotid intima-media thickness, hs-CRP and TNF-alpha are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis. 2011;214:185–190.
   PubMed Web of Science ®Google Scholar
• Pasterkamp G, van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther 2010;8:1235–1237.
   PubMedGoogle Scholar
• Bu D, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22:165–170.
   PubMed Web of Science ®Google Scholar
• Huang IC, Frangakis C, Dominici F, Diette GB, Wu AW. Application of a propensity score approach for risk adjust-ment in profiling multiple physician groups on asthma care. Health Serv Res. 2005;40:253–278.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Pro-gram (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Risk assessment tool for estimation 10-year risk of developing hard CHD (myocardial infarction and coro-nary death). http://hp2010.nhIbihin.net/atpiii/calculator.asp?usertype=prof. Accessed March 12, 2012.
   Google Scholar
• Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352:1685–1695.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Inflammation in athero-sclerosis. J Am Co// CardioL 2009;54:2129–2138.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011203:1637–1646.
   Google Scholar
• Triant VA, Meigs JB, Grinspoon SK. Association of C-reac-tive protein and HIV infection with acute myocardial infarc-tion. J Acquire Immune Defic Syndr 2009;51:268–273.
   PubMed Web of Science ®Google Scholar
• Tien PC, Choi Al, Zolopa AR, et al. Inflammation and mor-tality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010;55:316–322.
   PubMed Web of Science ®Google Scholar
• Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166:64–70.
   PubMed Web of Science ®Google Scholar
• Feldman JG, Goldwasser P, Holman S, DeHovitzJ, Minkoff H. C-reactive protein is an independent predictor of mor-tality in women with HIV-1 infection. J Acquire Immune Defic Syndr 2003;32:210–214.
   PubMed Web of Science ®Google Scholar
• Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidaemias associated with antiretroviral therapy in HIV clinical practice. J Infect. 2004;49:283–290.
   PubMed Web of Science ®Google Scholar
• Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhib-itor-asociated hyperlipidemia: a pilot study. AIDS. 2000;14:1660–1662.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051–1058.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6:572–578.
   PubMed Web of Science ®Google Scholar
• Aslangul E, Assoumou L, Bitter R, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24:77–83.
   PubMed Web of Science ®Google Scholar
• Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52:387–395.
   PubMed Web of Science ®Google Scholar
• Peters SA, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Int Med. 2010;268:155–161.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010;106:204–209.
   PubMed Web of Science ®Google Scholar
• Crouse JR III, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. JAMA. 2007;297:1344–1353.
   PubMed Web of Science ®Google Scholar
• Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol. 2010;25:399–405.
   PubMed Web of Science ®Google Scholar
• Sing P, Kohr D, Kaps M, Blaes F. Influence of statins on MHC Class I expression. Ann N Y Acad Sci. 2009;1173:746–751.
   PubMed Web of Science ®Google Scholar
• Bu DX, Tarrio M, Grabie N, et al. Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest. 2010;120:1961–1970.
   PubMed Web of Science ®Google Scholar
• Mira E, Leon B, Barber DF, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol. 2008;181:3524–3534.
   PubMed Web of Science ®Google Scholar
• Moncunill G, Negredo E, Bosch L, et al. Evaluation of the anti-HIV activity of statins. AIDS. 2005;19:1697–1700.
   PubMed Web of Science ®Google Scholar
• Amet T, Nonaka M, Dewan MZ, et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 2008;10:471–480.
   PubMed Web of Science ®Google Scholar
• Negredo E, Clotet B, Puig J, et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS. 2006;20:619–621.
   PubMed Web of Science ®Google Scholar
• Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011203: 756–764.
   Google Scholar
• Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS. 2011;25: 1128–1131.
   PubMed Web of Science ®Google Scholar
• Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/ signal transducers and activators of transcription pathway in human vascular endothelial cells. Br J Pharmacol. 2010;159:1294–1303.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. Guidelines. Version 6.0. October 2011. http://www.europeanaidsclinicalsociety.org. Accessed March 12,2012.
   Google Scholar